author-photo

Xavier Parot

Takeda Pharmaceutical Company

3

Papers

7

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (5)